Skip to content

Investors Overview

Esperion is a pharmaceutical company passionately committed to developing and commercializing non-statin, once-daily, oral therapies to lower elevated low-density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid is being developed as a once-daily, oral inhibitor of ATP Citrate Lyase (ACL), and is designed to bring a targeted mechanism of action to address patients’ unmet medical needs.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title and Summary
Toggle Summary TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
Therapeutics developed using TransGenRx advanced protein expression technology to be used in collaborative research at Esperion and Cleveland Clinic targeting new therapies to treat cardio-metabolic disease.
Toggle Summary Tim Mayleben named President and CEO of Esperion Therapeutics
Founder Roger Newton becomes executive chairman and chief scientific officer.
Toggle Summary Noah Rosenberg, MD, Joins Esperion Therapeutics as Chief Medical Officer
Noah Rosenberg, MD, Joins Esperion Therapeutics as Chief Medical Officer Plymouth, MI [April 8, 2012] – Esperion Therapeutics, Inc. today announced the appointment of Noah Rosenberg, MD, as its chief medical officer (CMO).  Dr. Rosenberg will lead the Esperion clinical advisory board and will
Toggle Summary ETC-1002-008 Phase 2b Results to be Presented at the American College of Cardiology 64th Annual Scientific Session
Company to Host Webcast on Saturday, March 14, 2015 at 7:00 p.m. Pacific Time/10:00 p.m. Eastern Time
Toggle Summary Esperion to Report Third Quarter 2019 Financial Results November 6, 2019
ANN ARBOR, Mich., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets open. Bempedoic Acid Bempedoic acid is our lead, non-statin, orally available, once-daily, low-density